Shares of NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) have been given an average rating of “Buy” by the seven brokerages that are covering the stock, MarketBeat Ratings reports. Seven research analysts have rated the stock with a buy rating. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $33.80.
Several equities analysts recently weighed in on NAMS shares. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $31.00 price objective on shares of NewAmsterdam Pharma in a research note on Thursday, September 5th. Needham & Company LLC assumed coverage on NewAmsterdam Pharma in a report on Wednesday, August 28th. They issued a “buy” rating and a $36.00 target price on the stock.
Get Our Latest Stock Analysis on NAMS
NewAmsterdam Pharma Trading Down 0.9 %
NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) last issued its earnings results on Wednesday, August 7th. The company reported ($0.51) earnings per share for the quarter, topping the consensus estimate of ($0.59) by $0.08. The company had revenue of $2.28 million for the quarter, compared to analyst estimates of $2.20 million. As a group, research analysts anticipate that NewAmsterdam Pharma will post -2.06 EPS for the current year.
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of the stock. Jennison Associates LLC purchased a new position in NewAmsterdam Pharma during the first quarter worth $22,015,000. Artal Group S.A. acquired a new stake in shares of NewAmsterdam Pharma during the first quarter valued at $18,920,000. Janus Henderson Group PLC purchased a new stake in NewAmsterdam Pharma during the 1st quarter worth about $15,018,000. Decheng Capital LLC acquired a new position in NewAmsterdam Pharma in the 2nd quarter valued at about $7,684,000. Finally, Opaleye Management Inc. purchased a new position in NewAmsterdam Pharma in the 4th quarter valued at about $2,964,000. 89.89% of the stock is currently owned by institutional investors and hedge funds.
About NewAmsterdam Pharma
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
Featured Articles
- Five stocks we like better than NewAmsterdam Pharma
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- Stock Average Calculator
- MarketBeat Week in Review – 9/16 – 9/20
- Using the MarketBeat Dividend Yield Calculator
- Don’t Miss These 3 Retail Stocks for Fall Gains
Receive News & Ratings for NewAmsterdam Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewAmsterdam Pharma and related companies with MarketBeat.com's FREE daily email newsletter.